Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Concert Pharmaceutic (CNCE)

Concert Pharmaceutic (CNCE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Concert Pharmaceutic 65 HAYDEN AVENUE SUITE 3000N LEXINGTON MA 02421 USA

www.concertpharma.com P: 781-860-0045

Description:

Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States.

Key Statistics

Overview:

Market Capitalization, $K 401,241
Enterprise Value, $K 258,141
Shares Outstanding, K 47,938
Annual Sales, $ 32,580 K
Annual Net Income, $ -80,050 K
Last Quarter Sales, $ 10 K
Last Quarter Net Income, $ -28,900 K
60-Month Beta 0.52
% of Insider Shareholders 11.33%
% of Institutional Shareholders 70.63%
Float, K 42,507
% Float 88.67%
Short Volume Ratio 0.64

Growth:

1-Year Return 201.08%
3-Year Return -9.22%
5-Year Return -64.64%
5-Year Revenue Growth 19,064.71%
5-Year Earnings Growth 0.44%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.58 on 11/07/22
Latest Earnings Date 03/09/23
Earnings Per Share ttm -3.12
EPS Growth vs. Prev Qtr 1.69%
EPS Growth vs. Prev Year 25.64%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CNCE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -109.43%
Return-on-Assets % -76.65%
Profit Margin % -245.70%
Debt/Equity 0.00
Price/Sales 8,134.05
Price/Cash Flow N/A
Price/Book 3.01
Book Value/Share 2.78
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar